OptimizeRx Corp

OptimizeRx Corp(OPRX)股票分析

$8.670

-1.015 (-11.71%)收盘时

Loading chart…
最高
9.915
开盘
9.850
成交量加权均价
9.00
成交量
234.62K
市值
188.54M
最低
8.420
成交额
2.11M
企业价值/息税折旧摊销前利润(TTM)
47.11

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

AI 分析 of OptimizeRx Corp (OPRX)

买入

OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.

分析师评级(1)

上行空间 +180.62%
买入
1 买入
0 持有
0 卖出
当前: 8.67
最低
17.00
平均
24.33
最高
32.00

B. Riley

2026-09-29

目标价

$11

买入

Stifel

2026-08-13

目标价

$12

买入

B. Riley

2026-05-13

目标价

$10

买入

Lake Street

2026-05-13

目标价

$11

买入

Stifel

2026-05-13

目标价

$14

买入

估值指标

OptimizeRx Corp(OPRX)当前预期市盈率为 6.95,5 年平均预期市盈率为 43.69。

预期市盈率

低估
5 年均值 P/E
43.69
当前P/E
6.95
高估
77.00
低估
10.38

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
40.57
当前EV/EBITDA
47.11
高估
84.25
低估
-3.12

预期市销率

合理
5 年均值 P/S
3.57
当前P/S
1.74
高估
7.13
低估
0.02

Alphio AI 对 OPRX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%OPRX

$17.89

情景价格

基

基准

基准 · 50%OPRX

$16.60

情景价格

悲

悲观

悲观 · 25%OPRX

$15.41

情景价格

持有 OPRX 的大户

R

Rice Hall James & Associates, LLC

+ 持有OPRX

+6.45%

3个月收益率

事件时间线

2026-10-27 (ET)

08:00:00

OptimizeRx Partners with PulsePoint for Electronic Health Records

2026-09-22 (ET)

09:00:00

OptimizeRx Integrates Supply Path Optimization with The Trade Desk

2026-08-12 (ET)

17:00:00

OptimizeRx Appoints Andy D'Silva as CFO

16:31:00

OptimizeRx Q2 Revenue at $20.5M, Exceeds Expectations

16:30:00

Company Reiterates FY 2026 Guidance, Expects Revenue of $95M to $100M

资讯

OPRX 常见问题 —— 由 Alphio AI 解答

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

OptimizeRx Corp (OPRX) is a good buy right now, trading at $9.41 with a forward P/E of 6.91, which indicates strong potential for growth relative to its earnings. The RSI is at 69.86, suggesting that the stock is nearing overbought territory but still has room for further gains. The recent partnership with PulsePoint and the integration with OpenPath are expected to enhance revenue opportunities, positioning the company for recovery after a significant decline of 49.89% over the past year. However, the main risk is the current year-to-date change of -24.24%, indicating ongoing volatility and uncertainty in the market.

1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易